Search: onr:"swepub:oai:DiVA.org:uu-170556" > Effects of dapaglif...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 04535naa a2200409 4500 | |
001 | oai:DiVA.org:uu-170556 | |
003 | SwePub | |
008 | 120312s2012 | |||||||||||000 ||eng| | |
009 | oai:prod.swepub.kib.ki.se:124242358 | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-1705562 URI |
024 | 7 | a https://doi.org/10.1210/jc.2011-22602 DOI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1242423582 URI |
040 | a (SwePub)uud (SwePub)ki | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Bolinder, Janu Karolinska Institutet4 aut |
245 | 1 0 | a Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin |
264 | 1 | b The Endocrine Society,c 2012 |
338 | a print2 rdacarrier | |
520 | a Context:Dapagliflozin, a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, reduces hyperglycemia in patients with type 2 diabetes mellitus (T2DM) by increasing urinary glucose excretion, and weight loss is a consistent associated finding.Objectives:Our objectives were to confirm weight loss with dapagliflozin and establish through body composition measurements whether weight loss is accounted for by changes in fat or fluid components.Design and Setting:This was a 24-wk, international, multicenter, randomized, parallel-group, double-blind, placebo-controlled study with ongoing 78-wk site- and patient-blinded extension period at 40 sites in five countries.Patients:Included were 182 patients with T2DM (mean values: women 63.3 and men 58.6 yr of age; hemoglobin A1c 7.17%, body mass index 31.9 kg/m2, and body weight 91.5 kg) inadequately controlled on metformin.Intervention:Dapagliflozin 10 mg/d or placebo was added to open-label metformin for 24 wk.Main Outcome Measures:Primary endpoint was total body weight (TBW) change from baseline at wk 24. Key secondary endpoints were waist circumference and dual-energy x-ray absorptiometry total-body fat mass (FM) changes from baseline at wk 24, and patient proportion achieving body weight reduction of at least 5% at wk 24. In a subset of patients, magnetic resonance assessment of visceral adipose tissue (VAT) and sc adipose tissue (SAT) volume and hepatic lipid content were also evaluated.Results:At wk 24, placebo-corrected changes with dapagliflozin were as follows: TBW, −2.08 kg [95% confidence interval (CI) = −2.84 to −1.31; P < 0.0001]; waist circumference, −1.52 cm (95% CI = −2.74 to −0.31; P = 0.0143); FM, −1.48 kg (95% CI = −2.22 to −0.74; P = 0.0001); proportion of patients achieving weight reduction of at least 5%, +26.2% (95% CI = 15.5 to 36.7; P < 0.0001); VAT, −258.4 cm3 (95% CI = −448.1 to −68.6; nominal P = 0.0084); SAT, −184.9 cm3 (95% CI = −359.7 to −10.1; nominal P = 0.0385). In the dapagliflozin vs. placebo groups, respectively, serious adverse events were reported in 6.6 vs. 1.1%; events suggestive of vulvovaginitis, balanitis, and related genital infection in 3.3 vs. 0%; and lower urinary tract infections in 6.6 vs. 2.2%.Conclusions:Dapagliflozin reduces TBW, predominantly by reducing FM, VAT and SAT in T2DM inadequately controlled with metformin. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Radiologi och bildbehandling0 (SwePub)302082 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Radiology, Nuclear Medicine and Medical Imaging0 (SwePub)302082 hsv//eng |
700 | 1 | a Ljunggren, Östenu Uppsala universitet,Metabola bensjukdomar4 aut0 (Swepub:uu)osteljun |
700 | 1 | a Kullberg, Joelu Uppsala universitet,Enheten för radiologi4 aut0 (Swepub:uu)jokul377 |
700 | 1 | a Johansson, Larsu Uppsala universitet,Enheten för radiologi4 aut0 (Swepub:uu)larsjoha |
700 | 1 | a Wilding, John4 aut |
700 | 1 | a Langkilde, Anna Maria4 aut |
700 | 1 | a Sugg, Jennifer4 aut |
700 | 1 | a Parikh, Shamik4 aut |
710 | 2 | a Karolinska Institutetb Metabola bensjukdomar4 org |
773 | 0 | t Journal of Clinical Endocrinology and Metabolismd : The Endocrine Societyg 97:3, s. 1020-1031q 97:3<1020-1031x 0021-972Xx 1945-7197 |
856 | 4 | u https://academic.oup.com/jcem/article-pdf/97/3/1020/10416511/jcem1020.pdf |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-170556 |
856 | 4 8 | u https://doi.org/10.1210/jc.2011-2260 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:124242358 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.